Lotus Eye Hospital and Institute Limited (LOTUSEYE)
₹114.36 +4.53% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Lotus Eye's revenue was ₹17.1 Cr, and net profit ₹0.6 Cr; the operating margin was 17.3%.
| Q1 FY27 (₹ Cr) | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹17.1 | — | — |
| Operating profit | ₹2.9 | — | — |
| Net profit | ₹0.6 | — | — |
| EPS (₹) | 0.30 | — | — |
| Operating margin | 17.3% | — | — |
LOTUSEYE delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 72.85% of the LOTUSEYE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 80.85%. That is close to its usual level. Turnover was only ₹8 lakh, so a handful of trades can move this figure.
Delivery in the last 5 sessions: 89.9% · 73.3% · 81.7% · 83.2% · 72.8%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Lotus Eye Hospital and Institute Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate was issued by the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited, dated October 3, 2026. This filing confirms the processing of securities dematerialisation and rematerialisation requests. It is a standard regulatory submission with no impact on operations or earnings.
- Filing made pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
- Pertains to the quarter ended September 30, 2026
- Issued by RTA MUFG Intime India Private Limited on October 3, 2026
- Formally submitted to BSE and NSE on October 8, 2026
Lotus Eye Hospital and Institute Limited has issued notice for its 29th Annual General Meeting scheduled for September 23, 2026, via Video Conferencing. Key special resolutions include revising the remuneration of Managing Director Ms. Sangeetha Sundaramoorthy from ₹3.50 lakh to ₹6.00 lakh per month (₹72 lakh annually) effective August 10, 2026. The company is also seeking shareholder approval to continue paying ₹1.00 lakh per month (₹12 lakh annually) to Non-Executive Director Dr. K.S. Ramalingam for FY 2026-27. The cut-off date for e-voting eligibility is September 16, 2026.
- 29th AGM scheduled for September 23, 2026, with remote e-voting running from September 20 to September 22, 2026.
- Cut-off date for voting eligibility set as September 16, 2026.
- Proposed increase in MD Ms. Sangeetha Sundaramoorthy's remuneration from ₹3,50,000 to ₹6,00,000 per month (₹72,00,000 per annum).
- Proposed continuation of ₹1,00,000 per month remuneration to Non-Executive Director Dr. K.S. Ramalingam for FY 2026-27.
Lotus Eye Hospital and Institute Limited has launched 'Lotus Optique', a dedicated optical retail store at its SITRA campus in Coimbatore on August 27, 2026. The store integrates clinical eye care with retail eyewear and features ZEISS VISUFIT 1000 3D facial scanning technology for frame fitting. This aligns with the company's stated strategy to grow recurring retail revenues alongside hospital operations, which delivered Rs 17.06 cr in revenue in Q1 FY27 (Jun 2026). Capex and revenue potential for this specific outlet were not disclosed.
- Launched 'Lotus Optique' retail optical store at SITRA campus, Coimbatore on August 27, 2026
- Equipped with ZEISS VISUFIT 1000 3D facial scanning technology for automated frame selection
- Aimed at expanding recurring retail eyewear sales alongside clinical hospital services
- Company posted Q1 revenue of Rs 17.06 cr and PAT of Rs 0.61 cr for Jun 2026 quarter
Lotus Eye Hospital reported a 26.2% YoY increase in revenue from operations to Rs 17.06 Cr for the quarter ended June 30, 2026. Net profit grew by 12.6% YoY to Rs 0.61 Cr, showing a significant recovery from the net loss of Rs 0.32 Cr in the preceding quarter (March 2026). However, profitability was tempered by a sharp 330.7% YoY spike in finance costs and a 28.3% rise in employee benefit expenses. The company maintains a relatively low debt-to-equity ratio of 0.26 based on its Rs 60 Cr net worth.
- Revenue from operations increased 26.2% YoY to Rs 17.06 Cr from Rs 13.52 Cr.
- Net profit for the quarter stood at Rs 0.61 Cr, up from Rs 0.54 Cr in the same quarter last year.
- Finance costs surged to Rs 50.65 lakhs from Rs 11.76 lakhs YoY, a 330.7% increase.
- Employee benefit expenses rose 28.3% YoY to Rs 3.65 Cr.
- Achieved a turnaround from a net loss of Rs 31.95 lakhs in the preceding quarter (Q4 FY26).
Lotus Eye Hospital and Institute Limited has submitted its compliance certificate for the quarter ended June 30, 2026, as per SEBI (Depositories and Participants) Regulations. The certificate, issued by MUFG Intime India Private Limited on July 01, 2026, confirms that share dematerialization requests were handled according to regulatory timelines. It verifies that physical certificates were cancelled and the names of depositories were updated in the register of members. This is a routine administrative filing and does not impact the company's financial position, which recently reported a net loss of Rs 0.26 Cr for the quarter ended Dec 2025.
- Compliance certificate submitted for the quarter ended June 30, 2026
- Certificate issued by Registrar MUFG Intime India Private Limited on July 01, 2026
- Official filing submitted to BSE and NSE on July 06, 2026
- Confirmation that dematerialized securities are listed on exchanges under Scrip Code 532998
Lotus Eye Hospital and Institute Limited has announced the closure of its trading window for all designated persons and their relatives starting July 1, 2026. This mandatory regulatory step precedes the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The window will remain closed until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be notified at a later date.
- Trading window closure starts from July 1, 2026, for the Q1 FY2026-27 period.
- Closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
- The restriction applies to all Designated Persons and their immediate relatives.
- Trading window will reopen 48 hours after the announcement of the June quarter financial results.
- Board meeting date for result approval is yet to be finalized and intimated.
Lotus Eye Hospital and Institute Limited reported a modest revenue growth of 8.4% YoY for FY26, reaching ₹53.71 crore. However, the company's net profit saw a sharp decline from ₹73.93 lakhs in FY25 to just ₹8.04 lakhs in FY26, largely due to increased finance costs and depreciation. The fourth quarter (Q4 FY26) was particularly weak, resulting in a net loss of ₹31.95 lakhs compared to a profit of ₹25.23 lakhs in the same quarter last year. The company significantly increased its debt by approximately ₹11.43 crore to fund capital expenditures, which rose by over ₹10 crore.
- Annual revenue from operations increased to ₹5,371.41 lakhs in FY26 from ₹4,956.25 lakhs in FY25.
- Net profit for the full year plummeted by 89% YoY to ₹8.04 lakhs.
- Reported a net loss of ₹31.95 lakhs for Q4 FY26 against a profit of ₹25.23 lakhs in Q4 FY25.
- Finance costs surged to ₹85.92 lakhs from ₹35.50 lakhs following new borrowings of ₹1,142.97 lakhs.
- Property, Plant, and Equipment (PPE) increased to ₹5,918.30 lakhs from ₹4,874.18 lakhs, indicating heavy expansion-led investment.
Lotus Eye Hospital and Institute Limited has approved its standalone audited financial results for the fiscal year ended March 31, 2026. The statutory auditors issued an unmodified opinion, suggesting that the financial statements present a true and fair view of the company's affairs. Additionally, the board has reappointed Mr. P Vishnu Adithan as the Internal Auditor for the 2026-27 financial year. These decisions were finalized during a board meeting held on May 26, 2026.
- Approved standalone audited financial results for the quarter and year ended March 31, 2026
- Statutory auditors provided an unmodified opinion on the financial results
- Reappointed Mr. P Vishnu Adithan, Chartered Accountant, as Internal Auditor for FY 2026-27
- Board meeting conducted on May 26, 2026, lasting 45 minutes from 05:15 PM to 06:00 PM
Lotus Eye Hospital and Institute Limited has approved its standalone audited financial results for the quarter and fiscal year ended March 31, 2026. The company reported that the statutory auditors have issued an unmodified opinion, indicating no major concerns in the financial reporting. Additionally, the board has reappointed Mr. P Vishnu Adithan as the Internal Auditor for the financial year 2026-27 to ensure continued internal control oversight. The meeting was held on May 26, 2026, and concluded within 45 minutes.
- Board approved standalone audited financial results for the quarter and year ended March 31, 2026.
- Statutory auditors provided an unmodified opinion on the financial statements.
- Reappointed Mr. P Vishnu Adithan, Chartered Accountant, as Internal Auditor for FY 2026-27.
- The board meeting commenced at 05:15 PM and concluded at 06:00 PM on May 26, 2026.
Lotus Eye Hospital and Institute Limited has informed the stock exchanges that it does not meet the criteria to be classified as a 'Large Corporate' as of March 31, 2026. This assessment follows the guidelines set by SEBI Circular SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 regarding mandatory fund raising through debt securities. As a result, the company is not subject to the specific borrowing and disclosure requirements mandated for larger entities. This is a routine annual compliance filing that clarifies the company's regulatory standing regarding debt issuance.
- Confirmed non-applicability of Large Corporate framework as of March 31, 2026.
- Compliance filing pursuant to SEBI Circular dated October 19, 2023.
- The company is not mandated to raise incremental borrowings through debt securities under this specific regulation.
Lotus Eye Hospital and Institute Limited has notified the exchanges regarding the closure of its trading window for designated persons starting April 1, 2026. This action is taken in accordance with SEBI Insider Trading regulations ahead of the audited financial results for the quarter and year ending March 31, 2026. The window will remain closed until 48 hours after the financial results are publicly disclosed. The company will announce the specific date for the board meeting to approve these results at a later time.
- Trading window closure effective from April 1, 2026.
- Closure pertains to the audited financial results for the quarter and year ending March 31, 2026.
- Restriction applies to designated persons and their immediate relatives.
- Window to reopen 48 hours after the declaration of financial results.
Lotus Eye Hospital and Institute Limited has decided to withdraw its proposal for voluntary delisting from the National Stock Exchange (NSE). The Board of Directors, in their meeting on March 17, 2026, cited current market conditions and the necessity of maintaining liquidity for investors as key reasons for this decision. Consequently, the company's equity shares will continue to be listed and traded on both the BSE and NSE. This reversal ensures that shareholders retain maximum flexibility and convenience for trading their holdings.
- Board decided not to proceed with the voluntary delisting of equity shares from the NSE
- Company will maintain its dual listing status on both BSE Limited and NSE
- Decision influenced by current market conditions and the need to ensure investor liquidity
- Board meeting concluded at 5:00 PM on March 17, 2026
BSE and NSE have imposed a combined fine of ₹4,34,240 (₹2,17,120 each) on Lotus Eye Hospital and Institute Limited for the quarter ended December 31, 2025. The penalty was levied due to non-compliance with Regulation 17(1A) of SEBI (LODR) Regulations, 2015. The company has clarified that the non-compliance was rectified through a shareholder resolution passed via Postal Ballot on January 17, 2026. Management maintains that this fine will have no material impact on the company's financial or operational activities.
- BSE and NSE imposed a fine of ₹2,17,120 each, totaling ₹4,34,240 inclusive of GST.
- The fine pertains to non-compliance with SEBI LODR Regulation 17(1A) regarding director appointments/continuance.
- Non-compliance was rectified via a Postal Ballot resolution deemed passed on January 17, 2026.
- The company previously paid fines for the same non-compliance for the quarter ended September 30, 2025.
- Management confirms no material impact on financial operations due to this penalty.
Lotus Eye Hospital and Institute Limited has addressed the imposition of fines by BSE and NSE regarding non-compliance with SEBI (LODR) Regulation 17(1A). The dispute arose from a difference in interpretation regarding whether a change in a director's designation constitutes a new appointment requiring specific approvals for directors over 75 years of age. While the company maintained a different view, it has since paid the fine and committed to full compliance with law in letter and spirit. The board reviewed these developments on February 11, 2026, to reinforce corporate governance standards.
- BSE and NSE imposed fines for non-compliance with SEBI (LODR) Regulation 17(1A) concerning director appointments.
- The company disputed the exchanges' view that a change in designation is equivalent to a new appointment.
- Lotus Eye Hospital has officially paid the fine to both stock exchanges to resolve the regulatory issue.
- The Board of Directors reaffirmed its commitment to corporate governance in a meeting held on February 11, 2026.
Lotus Eye Hospital and Institute Limited has appointed Mr. Prathish S as its new Company Secretary and Compliance Officer, effective February 13, 2026. The appointment was approved by the Board of Directors on February 11, 2026, following recommendations from the Nomination and Remuneration Committee. Mr. Prathish S is an Associate Member of the ICSI (A73669) and an alumnus of the prestigious Shri Ram College of Commerce. This transition fills a Key Managerial Personnel (KMP) role responsible for corporate governance and regulatory reporting.
- Appointment of Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.
- The appointee is an Associate Member of ICSI with Membership No. A73669.
- Educational background includes a degree from Shri Ram College of Commerce (SRCC), University of Delhi.
- The Board of Directors approved the appointment in a meeting held on February 11, 2026.
Financial Performance
Revenue Growth by Segment
Revenue from operations for FY21 was INR 32.37 Cr, representing a 20.18% decline from INR 40.55 Cr in FY20, primarily due to pandemic-related disruptions. However, Q4 FY21 showed a strong recovery with revenue of INR 10.57 Cr, growing 29.36% YoY from INR 8.17 Cr. The business is primarily a single-segment healthcare provider focusing on ophthalmology.
Geographic Revenue Split
The company operates across Tamil Nadu and Kerala. Key locations include Coimbatore (RS Puram, Peelamedu, Saravanampatti), Salem, Tirupur, Mettupalayam, and Karur in Tamil Nadu, and Kochi (Kadavanthara, Mulanthuruty) in Kerala. While specific % splits per city are not disclosed, Tamil Nadu remains the primary revenue contributor.
Profitability Margins
For FY21, the company reported a Profit Before Tax of INR 1.91 Cr on a Total Income of INR 33.11 Cr, yielding a margin of 5.77%. In Q2 FY26 (quarter ended Sept 30, 2025), the Net Profit was INR 11.58 lakhs on a Total Income of INR 13.04 Cr, showing a significant margin compression to approximately 0.89% compared to previous periods.
EBITDA Margin
Operating profitability for FY21 (calculated as Total Income minus operating expenses excluding depreciation and finance costs) was approximately INR 4.65 Cr, representing an EBITDA margin of 14.04%. This was a decrease from the previous year's higher base due to fixed employee costs (INR 6.97 Cr) and other expenses (INR 14.38 Cr) despite lower revenue.
Capital Expenditure
For the half-year ended September 30, 2025, the company invested INR 1.66 Cr in the purchase of property, plant, and equipment. This reflects ongoing upgrades to medical technology and facility maintenance.
Credit Rating & Borrowing
Not disclosed in available documents; however, finance costs for the period ended September 30, 2025, were reported at INR 22.68 lakhs, indicating manageable debt levels or lease liabilities.
Operational Drivers
Raw Materials
Medical consumables (lenses, surgical kits, medicines) and stock-in-trade (optical frames and spectacles). Cost of materials consumed represented 15.7% of revenue (INR 5.09 Cr) in FY21, while purchase of stock-in-trade accounted for 14.7% (INR 4.76 Cr).
Import Sources
Not specifically disclosed, but medical equipment and high-end intraocular lenses are typically sourced from global medical technology hubs or domestic distributors in India.
Capacity Expansion
The company operates multiple centers across 7+ locations. Recent expansions include the addition of new board members and a focus on 'Green Business' practices at the Salem branch, which was ranked 1st runner-up in the Rotary Club Salem Green Business Awards 2020.
Raw Material Costs
Total material and stock costs for FY21 were INR 9.85 Cr, roughly 30.4% of revenue. Procurement strategies involve a mix of direct consumption for surgeries and retail stock for optical outlets.
Manufacturing Efficiency
In Q4 FY21, the company screened 2,800+ eyes and registered 5,000+ new patients, indicating high throughput and utilization of clinical staff post-COVID.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
The company is focusing on enhancing recurring revenue through its optical retail and pharmacy wings. It is also aggressively pursuing digital marketing (1.76 Cr ad impressions) and national television promotions (Star Vijay) to increase brand visibility. Expansion is driven by corporate and public eye camps (2,800+ screened in Q4 FY21) to build a patient pipeline.
Products & Services
Ophthalmology services including Cataract surgery, LASIK, Glaucoma treatment, and Optometry. Retail sales of spectacles, frames, and contact lenses.
Brand Portfolio
LOTUS, Lotus Eye Hospital and Institute.
New Products/Services
Establishment of efficient and accessible optometry institutions and counseling centers for the underprivileged to expand the service ecosystem.
Market Expansion
Targeting deeper penetration in the Tamil Nadu and Kerala markets through satellite centers and community outreach programs.
Market Share & Ranking
Not disclosed in available documents, but recognized as a leading eye care provider in the Coimbatore and Salem regions.
Strategic Alliances
Partnerships with organizations like the Rotary Club for community health initiatives and 'Green Business' certifications.
External Factors
Industry Trends
The eye care industry is shifting toward technology-heavy diagnostics and minimally invasive surgeries. Lotus is positioning itself by investing in digital branding and modernizing its equipment (INR 1.66 Cr Capex in H1 FY26).
Competitive Landscape
Competes with regional eye care chains and multi-specialty hospitals in South India.
Competitive Moat
The company's moat is built on its 25+ year brand legacy in South India, a network of specialized hospitals, and a new management team led by MD Ms. Sangeetha Sundaramoorthy. This regional reputation acts as a barrier to entry for new competitors.
Macro Economic Sensitivity
Highly sensitive to healthcare spending and elective surgery demand. GDP growth and rising middle-class disposable income drive demand for premium eye care services like LASIK.
Consumer Behavior
Increasing awareness of eye health and rising prevalence of digital eye strain are driving higher patient volumes for optometry and corrective procedures.
Geopolitical Risks
Limited, as operations are domestic, but global supply chains for medical equipment could be affected by trade barriers.
Regulatory & Governance
Industry Regulations
Subject to the Companies Act 2013, SEBI LODR 2015, and healthcare-specific standards. Non-compliance with Regulation 17(1A) led to monetary penalties in 2025.
Environmental Compliance
The Salem unit received a 'Green Business' award, indicating a focus on sustainable operations, though specific ESG costs are not quantified.
Taxation Policy Impact
The company faces uncertain tax positions related to direct and indirect taxes, which are subject to periodic challenges by authorities. Current tax for Q2 FY26 was INR 27.09 lakhs.
Legal Contingencies
The company has disclosed pending litigations in Note 44 of its financial statements. While the specific INR value is not provided in the summary, these include tax matters and other legal challenges that could impact the financial position.
Risk Analysis
Key Uncertainties
Regulatory risks regarding board composition and SEBI compliance (potential for further fines). Operational risks include the ability to attract and retain specialized surgeons.
Geographic Concentration Risk
100% of revenue is concentrated in Tamil Nadu and Kerala, making the company vulnerable to regional economic or regulatory changes in these two states.
Third Party Dependencies
Dependency on medical equipment manufacturers for maintenance and supply of specialized surgical consumables.
Technology Obsolescence Risk
High risk in the ophthalmology sector; failure to upgrade to the latest LASIK or diagnostic technology could result in loss of market share to more modern facilities.
Credit & Counterparty Risk
Trade receivables stood at INR 2.15 Cr as of September 30, 2025, indicating a relatively low credit risk given the cash-and-carry nature of most healthcare services.
